Abstract
Background There is a concern that low initial SARS-CoV-2 antibody titers in individuals may drop to undetectable levels within months after infection. Although this may raise concerns over long term immunity, both the antibody levels and avidity of the antibody-antigen interaction should be examined to understand the quality of the antibody response.
Methods A testing-on-a-probe “plus” panel (TOP-Plus) was developed, which included a newly developed avidity assay built into the previously described SARS-CoV-2 TOP assays that measured total antibody (TAb), surrogate neutralizing antibody (SNAb), IgM and IgG on a versatile biosensor platform. TAb and SNAb levels were compared with avidity in previously infected individuals at 1.3 and 6.2 months post-infection in paired samples from 80 COVID-19 patients.
Results The newly designed avidity assay in this TOP panel correlated well with a reference Bio-Layer Interferometry avidity assay (R=0.88). The imprecision of the TOP avidity assay was less than 9%. Although TAb and neutralization activity (by SNAb) decreased between 1.3 and 6.2 months post infection, the antibody avidity increased significantly (P < 0.0001).
Conclusion This highly precise and versatile TOP-Plus panel with the ability to measure SARS-CoV-2 TAb, SNAb, IgG and IgM antibody levels and avidity of individual sera on one sensor can become a valuable asset in monitoring not only SARS-CoV-2-infected patients, but also the status of individuals’ COVID-19 vaccination response.
Competing Interest Statement
Z.Z. received seed instruments and sponsored travel from ET Healthcare. Y.H. was funded by China Scholarship Council. The rest of the authors declare that they have no conflict of interests with the present work
Funding Statement
This work was supported by a COVID-19 research grant from Weill Cornell Medicine (M.C.), Weill Cornell Medicine Translational Research Program of the Department of Pathology and Laboratory Medicine at Weill Cornell Medicine (grant number COVID3376; Z.Z.). NIH grant R01 AI36082 (P.J.K.) and NIH grant P01-AI138398-S1 and 2U19AI111825 (M.C.N.). C.G. was supported by the Robert S. Wennett Post-Doctoral Fellowship, in part by the National Center for Advancing Translational Sciences (National Institutes of Health Clinical and Translational Science Award program, grant UL1 TR001866), and by the Shapiro-Silverberg Fund for the Advancement of Translational Research. M.C.N. is a Howard Hughes Medical Institute Investigators.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by Rockefeller University (IRB# DRO-1006) and determined to meet exemption requirements by Weill Cornell Medicine Institutional Review Board.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
An anonymized dataset and data analysis code may be available upon application to the corresponding author and institutional review as per Weill Cornell Medicine data sharing policies
Abbreviation list
- COVID-19
- Corona Virus Disease-2019
- SARS-CoV-2
- Severe Acute Respiratory Syndrome Coronavirus 2
- RT-PCR
- real-time polymerase chain reaction
- RBD
- receptor-binding domain
- TOP
- testing-on-a-probe
- HPLC
- high performance liquid chromatography
- SRID
- single radial immunodiffusion
- SPR
- Surface Plasmon Resonance
- BLI
- Bio-Layer Interferometry
- RFU
- relative fluorescence unit
- dR
- relative dissociation rate
- TAb
- total antibody
- SNAb
- surrogate neutralizing antibody
- ELISA
- Enzyme-linked immunosorbent assays
- PRNT
- plaque reduction neutralization test
- PsV
- pseudo virus neutralization test
